Thyroid hormone receptor-beta

Class

THR-beta agonist

Thyroid hormone receptor-beta (THR-beta) is one of two nuclear receptor subtypes through which thyroid hormone (triiodothyronine, T3) acts. Nuclear receptors are proteins that bind hormone signals and then directly regulate gene transcription. THR-beta predominates in liver, and to a lesser extent pituitary, where thyroid hormone signaling increases fatty-acid oxidation, cholesterol clearance, and mitochondrial activity. The other subtype, THR-alpha, predominates in heart, bone, and skeletal muscle, where thyroid hormone signaling raises heart rate and metabolic turnover. Because natural thyroid hormone activates both subtypes, generalized thyroid hormone excess produces beneficial liver effects alongside unwanted cardiac and skeletal effects. THR-beta-selective agonists are designed to reproduce the liver benefits, chiefly lowering circulating lipids and hepatic fat content, while minimizing activation of THR-alpha in the heart and bone. This selectivity rationale makes the mechanism relevant to metabolic liver disease involving fat accumulation and to disorders of abnormal lipid metabolism, where reducing hepatic triglyceride and cholesterol burden is a therapeutic goal without inducing systemic hyperthyroid-like side effects. The approach reflects a broader pharmacological strategy of exploiting subtype or tissue selectivity to separate a hormone's desired action from its off-target physiological consequences.